Articles related to CLINICAL TRIALS

The study, led by Michael Bretthauer, MD, PhD, of the University of Oslo in Norway, found that people who were invited to have a screening colonoscopy had a lower risk of colorectal cancer than those who were not, though at a lower rate than researchers expected. Furthermore, no significant difference in colorectal cancer-related mortality was discovered between the two groups.

The phase 1 EXPLORER and phase 2 PATHFINDER trials demonstrated that avapritinib can produce complete and long-lasting clinical responses as well as molecular remission in KIT D816V patients. The complex mutational landscape of AdvSM, which is frequently associated with a hematologic neoplasm, poses significant management challenges.

First-line pembrolizumab and pembrolizumab-chemotherapy continued to outperform cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma after a 4-year follow-up. Following pembrolizumab-based therapy, patients responded well to subsequent treatment.

This MashupMD link provides a video critique on YouTube of an NEJM paper on colonoscopy screening.

Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial The rates of grades 2, 3, 4, and 5 toxic effects were 14.2%, 4.2%, 0%, and 0.3%, respectively, in this population-based phase 2 nonrandomized clinical trial of 381 patients with oligometastatic or oligoprogressive disease that was designed to capture toxic effects prospectively as the primary end point.

Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.